1. Academic Validation
  2. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase

Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase

  • J Med Chem. 1997 May 23;40(11):1570-7. doi: 10.1021/jm970041e.
J A Robl 1 C Q Sun J Stevenson D E Ryono L M Simpkins M P Cimarusti T Dejneka W A Slusarchyk S Chao L Stratton R N Misra M S Bednarz M M Asaad H S Cheung B E Abboa-Offei P L Smith P D Mathers M Fox T R Schaeffer A A Seymour N C Trippodo
Affiliations

Affiliation

  • 1 Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.
Abstract

A series of 7,6- and 7,5-fused bicyclic thiazepinones and oxazepinones were generated and incorporated as conformationally restricted dipeptide surrogates in mercaptoacyl Dipeptides. These compounds are potent inhibitors of angiotensin-converting Enzyme (ACE) and neutral endopeptidase (NEP) both in vitro and in vivo. Compound 1a, a 7,6-fused bicyclic thiazepinone, demonstrated excellent blood pressure lowering in a variety of animal models characterized by various levels of plasma Renin activity and significantly potentiated urinary sodium, ANP, and cGMP excretion in a cynomolgus monkey assay. On the basis of its potency and duration of action, compound 1a (BMS-186716) was advanced into clinical development for the treatment of hypertension and congestive heart failure.

Figures
Products